Duration of protection against Bordetella pertussis infection elicited by whole-cell and acellular vaccine priming in Polish children and adolescents

被引:3
|
作者
Paradowska-Stankiewicz, Iwona [1 ]
Rumik, Agnieszka [1 ]
Bogusz, Joanna [1 ]
Zbrzezniak, Jakub [1 ]
Rastawicki, Waldemar [1 ]
Smietanska, Karolina [1 ]
Vargas-Zambrano, Juan C. [2 ]
Macina, Denis [2 ]
机构
[1] Natl Inst Publ Hlth, Natl Inst Hyg, Natl Res Inst, Ul Chocimska 24, PL-00791 Warsaw, Poland
[2] Sanofi Pasteur, 14 Espace Henry Vallee, F-69007 Lyon, France
关键词
Pertussis; Vaccines; Seroprevalence; Waning; REDUCED RISK; IMMUNITY; RECIPIENTS; DURABILITY; EXEMPTIONS; CALIFORNIA; DISEASE;
D O I
10.1016/j.vaccine.2021.08.105
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: In the context of reported resurgence of pertussis in the last decade, researchers hypothesized that acellular (aP) pertussis vaccines elicit a shorter-lived protection compared to whole-cell (wP) pertussis vaccines. However, in the studies seeking to demonstrate this hypothesis, exposure to each vaccine type was not concurrent, and contradictory epidemiologic modeling questioned its validity. The context of pertussis vaccination history in Poland, with both vaccine types used concurrently in comparable proportions, provided an opportunity to investigate this hypothesis. We sought to compare waning of protection by primary series vaccine type by measuring anti-pertussis toxin antibody concentrations as proxy for recent infection. Materials and methods: Serological samples from 2,745 children and adolescents aged >5 years and <16 years and with completed 5-dose pertussis vaccination series were tested by ELISA for pertussis toxin (PT) antibodies. Participants were stratified by type of priming vaccine (wP or aP). Vaccination timeliness and priming-specific trends in anti-PT antibody levels by time since last vaccine dose were analyzed. Results: A total of 1,161 (42.5%) children received wP vaccines, and 1,314 (48.1%) received aP vaccines for their primary series and toddler booster. Overall, 53.57% of the subjects received doses 2-4 in a timely manner, while only 41.52% received all 5 doses at the recommended intervals. Using GMCs or seropositivity measures, both priming groups showed a re-increase in anti-PT antibody levels signing infection in recent years from 8 years after the school-entry booster onward. Comparisons did not show any significant differences between the two groups in the timing or intensity of this re-increase. Conclusion: Our results clearly confirm that vaccine-elicited immunity against pertussis wanes among adolescents even after a complete infant, toddler and school-entry vaccination series. The timing and intensity of the waning of protection appear similar with whole-cell as with acellular pertussis vaccines. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:6067 / 6073
页数:7
相关论文
共 50 条
  • [1] Priming with Whole-Cell versus Acellular Pertussis Vaccine
    Liko, Juventila
    Robison, Steve G.
    Cieslak, Paul R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (06): : 581 - 582
  • [2] Modeling the Effects of Priming With the Whole-Cell Bordetella Pertussis Vaccine
    Snelling, Thomas
    McIntyre, Peter
    JAMA PEDIATRICS, 2016, 170 (12) : 1228 - 1229
  • [3] Less reactogenic whole-cell pertussis vaccine confers protection from Bordetella pertussis infection
    Skopova, Karolina
    Holubova, Jana
    Bockova, Barbora
    Slivenecka, Eva
    de Barros, Joao Melo Santos
    Stanek, Ondrej
    Sebo, Peter
    MSPHERE, 2025,
  • [4] Epidemiological and Economic Effects of Priming With the Whole-Cell Bordetella pertussis Vaccine
    DeAngelis, Haedi
    Scarpino, Samuel V.
    Fitzpatrick, Meagan C.
    Galvani, Alison P.
    Althouse, Benjamin M.
    JAMA PEDIATRICS, 2016, 170 (05) : 459 - 465
  • [5] Proteomics of Bordetella pertussis whole-cell and acellular vaccines
    Jens Möller
    Max Edmund Kraner
    Andreas Burkovski
    BMC Research Notes, 12
  • [6] Proteomics of Bordetella pertussis whole-cell and acellular vaccines
    Moeller, Jens
    Kraner, Max Edmund
    Burkovski, Andreas
    BMC RESEARCH NOTES, 2019, 12 (1)
  • [7] Whole-cell pertussis vaccine protects against Bordetella pertussis exacerbation of allergic asthma
    Ennis, DP
    Cassidy, JP
    Mahon, BP
    IMMUNOLOGY LETTERS, 2005, 97 (01) : 91 - 100
  • [8] GLUTARALDEHYDE IN WHOLE-CELL BORDETELLA-PERTUSSIS VACCINE
    ARYA, SC
    ASHRAF, SJ
    PATHAK, VP
    VACCINE, 1989, 7 (06) : 486 - 486
  • [9] Whole-Cell and Acellular Pertussis Vaccine: Reflections on Efficacy
    Alghounaim, Mohammad
    Alsaffar, Zainab
    Alfraij, Abdulla
    Bin-Hasan, Saadoun
    Hussain, Entesar
    MEDICAL PRINCIPLES AND PRACTICE, 2022, 31 (04) : 313 - 321
  • [10] Antibody Response from Whole-Cell Pertussis Vaccine Immunized Brazilian Children against Different Strains of Bordetella pertussis
    Pereira, Alexandre
    Pietro Pereira, Aparecida S.
    Silva, Celio Lopes
    Rocha, Gutemberg de Melo
    Lebrun, Ivo
    Sant'Anna, Osvaldo A.
    Tambourgi, Denise V.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2010, 82 (04): : 678 - 682